Men's Health

Ten percent of men with penile implants express dissatisfaction with their implant, and 12% either do not use their implant or use it less often than desired, according to data from a patient registry known as PROPPER (Prospective Registry of Outcomes with Penile Prostheses for Erectile Restoration).

In this article, we review the etiology and pathophysiology of ED in this challenging patient population and provide an approach to treatment and risk reduction via lifestyle modification and pharmacologic intervention.

Long-term functional outcomes after radical prostatectomy are excellent, regardless of surgical technique, when the procedure is performed by experienced surgeons at a high-volume center, according to a recent study.

Learn more about these products as well as a powered exam table and an app that measures, monitors, and helps improve fertility in men.

The proposed clinical quality measure comes as a pair of JAMA studies note a decline in screening since the USPSTF recommended against screening.

Recent developments in PSA screening point out why policy truly does matter to residents, writes Alan L. Kaplan, MD, in this blog post.

In her first blog post for Urology Times, nurse practitioner Adele M. Caruso, MSN, CRNP, provides an update on the ongoing PSA screening debate and discusses helpful resources to use when questions on screening arise.

Dr. Goldstein and Dr. Li’s video highlights crucial steps to performing a successful no-scalpel vasectomy, says Cigdem Tanrikut, MD.

This video demonstrates the steps of a minimally invasive, no-scalpel vasectomy technique using titanium hemoclips and electrocautery.

Oncologic outcomes are similar using focal cryotherapy and focal high-intensity focused ultrasound for treatment of localized prostate cancer, French urologists reported at the World Congress of Endourology and SWL in London.

Dietitian Mary M. Flynn, PhD, RD, LDN, looks at this and several other misconceptions.

Other pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.

The recently published AUA practice guideline on Peyronie’s disease provides current clinical principles on diagnosis and treatment of a highly prevalent and clinically significant condition, according to the co-chair of the multidisciplinary panel that developed the guideline.

Findings from a retrospective study lend support to the idea that even in men with a Gleason 7 (3+4) biopsy score, prostate cancer may sometimes act like low-risk disease.

The test could be a step closer to personalized risk-based prostate cancer diagnostic programs, study authors say.

Researchers say they’ve uncovered a wide variation in costs to treat low-risk prostate cancer.

Movember is a global movement that leverages the power of the mustache to promote men's health. Hear from Brian Stork, MD as he shares insight into what Movember means for him and what you need to know.

“The best way to avoid overtreatment is to avoid overdiagnosis. MRI allows you to do that," says Mark Emberton, MD.

In this case study, a man in his fifth decade of life complained of right side testicular swelling that had persisted for 2 weeks. He reported no pain.

Other products highlighted in this slideshow include a trial system for incontinence therapy, a compact catheter, a wearable digital technology solution for continence care assessment and management, and laser fiber and sheath system.

Over the last 5 years, we have developed a comprehensive, multispecialty, hospital-based men's health center, and we believe that the following five elements are the keys to its success.

A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.

Don't count out men who have not recovered urinary and erectile function at 12 months after radical prostatectomy.

This slideshow presents a case study of a 30-year-old male with discomfort in left groin region due to mass/swelling for 1 year.

The Sonablate 450, SonaCare Medical’s high-intensity focused ultrasound (HIFU) device, has received FDA clearance for prostate tissue ablation.

New study findings from the Ronald Reagan UCLA Medical Center, Los Angeles add evidence supporting the potential for targeted magnetic resonance-ultrasound (MR-US) fusion biopsy to improve the diagnosis of prostate cancer. Learn more

Shock wave therapy has now been subjected to multiple randomized, placebo-controlled, and additional open-label studies in clinics worldwide, demonstrating impressive efficacy and safety.

In this interview, Peter L. Choyke, MD, discusses current methods of detecting biochemical recurrence with imaging, promising new techniques to localize recurrence, and cost considerations.

Phase II study results show that daily treatment with abiraterone acetate (ZYTIGA), 1,000 mg, plus prednisone, 5 mg was very effective in lowering PSA levels in men with non-metastatic castrate-resistant prostate cancer (CRPC) at high risk for metastasis. Learn more

Positron emission tomography with a 68Gallium-labeled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA-PET hybrid imaging) is a promising new diagnostic tool for staging prostate cancer, according to German urologists who presented their experience at the American Society of Clinical Oncology annual meeting in Chicago. Get results